Friulimicin B

Drug Profile

Friulimicin B

Alternative Names: Friulimicin; Friulimycin B; Lipopeptide - Merlion Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis Pharmaceuticals
  • Developer MerLion Pharmaceuticals
  • Class Antibacterials; Lipopeptides
  • Mechanism of Action Bacterial polysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Nosocomial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Nosocomial-infections in Singapore (Topical)
  • 05 Jan 2011 Friulimicin B is available for licensing as of 05 Jan 2011.
  • 05 Jan 2011 Preclinical trials in Nosocomial infections in Singapore (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top